Pharma Focus Asia
KP - Choose our fully recyclable blister films

Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico

Thursday, July 27, 2023

Hummingbird Bioscience has announced a significant step in advancing clinical development by initiating two Phase IB clinical trials in Australia.

The focus of the trials will be on evaluating the activity of HMBD-001, a differentiated HER3-targeting antibody that specifically inhibits HER3 oncogenic signalling. The two patient groups being studied are those with squamous non-small cell lung carcinoma (sqNSCLC) and patients with genetic aberrations in HER3 signalling.

By collaborating with Omico, Hummingbird Bioscience gains access to the PrOSPeCT initiative and network in Australia. Omico's PrOSPeCT initiative will play a crucial role in accelerating the clinical development of HMBD-001 by providing patient referrals to the trials.

Collaborations between Hummingbird Bioscience and Omico represent a step forward in creating a more sustainable and research-led model of healthcare. Together, this partnership has the potential to contribute significantly to advancements in precision medicine and ultimately lead to better outcomes for cancer patients.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023
MasterControl - 6 Essential Features in an eQMS